+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness of focal mass drug administration fMDA in reducing the incidence of Plasmodium vivax malaria in the Loreto Department of Peru. This open-label cluster-randomized controlled trial compares standard malaria control interventions with additional targeted drug administration in high-risk village clusters. The study aims to assess the impact of fMDA on malaria transmission, safety, and cost-effectiveness over a three-year period in a low transmission setting. Participants live in villages randomized to either standard malaria control measures or fMDA. Standard interventions include insecticide-treated bednets, management of mosquito breeding sites, symptomatic case detection, and treatment. The fMDA group receives two rounds of targeted antimalarial drugs per cycle, repeated for three cycles. Drugs used include chloroquine, tafenoquine, and primaquine, with dosing based on age and G6PD status. High-risk individuals are those living within 200 meters of confirmed malaria cases in the past two years. Testing and counseling for G6PD deficiency are done before drug administration. Participants are monitored through baseline and endline surveys collecting dried blood spots and fever screening with treatment per national guidelines. Safety is evaluated by tracking severe adverse events and malaria cases. Cost-effectiveness and acceptability of the intervention are also measured. The primary outcome is the cumulative incidence of P. vivax infection over 36 months. The trial is conducted pragmatically through the existing health system with follow-up extending over four years.

All AgesAll GendersPhase 3
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying how three different menstrual products menstrual pads, tampons, and menstrual cups affect the bacterial makeup of the vaginal microbiome. This study takes place across three countries Peru, Cameroon, and Switzerland. The goal is to understand how these products influence vaginal health by following participants over several menstrual cycles. The study uses a randomized crossover design without a dedicated control group, allowing each participant to use all three products in different orders. Participants will be randomly assigned to one of six sequences, each involving the use of tampons, cups, and pads for two menstrual cycles each. This means each participant will use each product for about two months, totaling six months of study participation. Self-sampling kits will be provided, containing swabs for collecting vaginal microbiome samples at three points during each menstrual cycle. Participants will collect vaginal swab samples themselves during their menstrual cycles and provide self-reported information on vaginal health complaints monthly. Researchers will analyze various measures such as the balance of specific bacteria, vaginal pH, bacterial diversity, and molecular biomarkers. These assessments will occur monthly throughout the six-month study. This detailed monitoring aims to reveal how menstrual products impact vaginal bacterial communities and overall vaginal health.

Age: 18Years - 35YearsFEMALEPhase Not Applicable
3 locations